On June 3, Gelonghui announced that Yimingangk-B (01541.HK) has received approval from the Drug Evaluation Center of the National Medical Products Administration (NMPA) to conduct phase III clinical trials of IMM01 (Tirapazamine) in combination with Azacytidine, for first-line treatment of chronic myelomonocytic leukemia (CMML).
宜明昂科-B(01541.HK)：IMM01(替达派西普)联合阿扎胞苷获国家药监局批准进行CMML一线治疗的III期临床试验
Yiming Angko-B (01541.HK): IMM01 (tidapecip) combined with azacitidine was approved by the State Drug Administration for phase III clinical trial of CMML first-line treatment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.